Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02043665
Title Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM)
Acronym STORM
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Viralytics
Age Groups: senior | adult
Covered Countries USA | GBR | AUS

No variant requirements are available.